Huang JTH, Cole AP, Mossanen M, et al. - In this research, the effect of alvimopan in patient undergoing radical cystectomy (RC) for bladder cancer was investigated. Researchers distinguished individuals who had undergone elective RC for bladder cancer from 2009 to 2015 in the Premier Healthcare Database, a nationwide, all-payer hospital-based database, and compared patients who received and did not receive alvimopan in the perioperative period. The study cohort included a sum of 1087 patients with 511 patients receiving perioperative alvimopan, after applying the inclusion criteria. The data reveal that the patients undergoing radical cystectomy, alvimopan is correlated with a substantial cost-saving, and imply that routine usage of alvimopan may be a potential cost-effective strategy to decrease the overall financial burden of bladder cancer.